Knee Arthritis OsteoarthritisPhase 4PRECISION-KneeNCT07544576
Comparing Treatment of Knee Osteoarthritis With Triamcinolone Injections Using 40mg With Landmark Guidance and 20mg With Ultrasound Guidance
A Phase 4 study testing Triamcinolone knee injection without ultrasound guidance and Triamcinolone knee injection with ultrasound guidance in people with Knee Arthritis Osteoarthritis, run by Sosi Dzhugarian at 4 sites in United States.
Trial summary
The purpose of this study is to determine whether a lower dose of corticosteroid injection with ultrasound-guidance for the treatment of knee osteoarthritis can be as effective as a higher dose that is landmark-guided. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Knee Arthritis Osteoarthritis
- What is being tested?
- Triamcinolone knee injection without ultrasound guidance and Triamcinolone knee injection with ultrasound guidance
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 140 participants
- Where
- 4 sitesUnited States
- Study dates
- 12 Dec 2025to 8 Dec 2026
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects who have already been evaluated within at least one of the 4 study clinics with any of the 3 providers who will be administering the treatment
- Males or females age 50 and older
- Already had completion of imaging of the affected knee(s) via radiography and/or MRI
- Imaging demonstrates osteoarthritis of any severity
- Diagnosis of primary osteoarthritis of one or both knees
- One or more symptoms associated with the osteoarthritis of at least one knee
- Patients able to provide informed consent in English and/or Spanish
Who cannot join
- Skin infection at or near area of injection site
- Recent fracture of the same knee joint within past 6 months
- Uncontrolled bleeding disorder
- Intra-articular corticosteroid injection within past 3 months
- Intra-articular HA injection within the past 3 months
- Intra-articular PRP injection within the past 3 months
Show all 10Show fewer
- Presence of prosthetic knee joint in symptomatic knee
- Inability to report symptoms due to cognitive impairment
- Complete inability to ambulate, even with assistive device
- Any person who is pregnant or less than 1 year post-menopause
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States4 sites
Community Memorial Health Center - North Brent Street, 168 North Brent Street, Suite 302, Orthopedic Surgery Clinic, Ventura, California 93003
Ventura, California, 93003
Community Memorial Health Center - North Brent Street, 168 North Brent Street, Suite 302, Sports Medicine Clinic, Ventura, California 93003
Ventura, California, 93003
Community Memorial Health Center - Pirie Road, 117 Pirie Road, Orthopedic Surgery Clinic, Ojai, California 93023
Ventura, California, 93003
Community Memorial Health Center, 1320 Maricopa Highway, Ojai, California 93023
Ventura, California, 93003
About this study
Official title: Non-Inferiority Study Comparing Treatment of Primary Knee Osteoarthritis With Intra-Articular Triamcinolone Injections Using 40mg With Landmark Guidance and 20mg With Ultrasound Guidance: The PRECISION-Knee Trial (PRospective Evaluation of the Clinical Impact of Steroid Injection Options iN Knee Osteoarthritis)
The purpose of this study is to determine whether a lower dose of corticosteroid injection with ultrasound-guidance for the treatment of knee osteoarthritis can be as effective as a higher dose that is landmark-guided. With landmark-guided dosing, it may be reasonable to use a higher amount of corticosteroid in order to ensure a sufficient amount of the medication is administered, however these injections carry the risk of side effects. Alternatively, with the use of ultrasound, it may be reasonable to use less corticosteroid, possibly decreasing the risk of side effects and increasing patient satisfaction.
- Conditions
- Knee Arthritis Osteoarthritis
- Being tested
- Triamcinolone knee injection without ultrasound guidance, Triamcinolone knee injection with ultrasound guidance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Triamcinolone knee injection without ultrasound guidanceDrug
3mL lidocaine (without epinephrine) 1% solution combined with 1mL triamcinolone acetonide injectable solution, USP (40mg per mL)
Triamcinolone knee injection with ultrasound guidanceCombination product
3mL lidocaine (without epinephrine) 1% solution combined with 0.5mL triamcinolone acetonide injectable solution, USP (40mg per mL)
| Study group | Role | What they receive |
|---|---|---|
| 40mg landmark-guided triamcinolone knee joint injection | Active comparator | Not described Receives: Drug: Triamcinolone knee injection without ultrasound guidance |
| 20mg ultrasound-guided triamcinolone knee injection | Experimental | Not described Receives: Combination Product: Triamcinolone knee injection with ultrasound guidance |
What is being measured
The primary outcome is the main question the study is designed to answer.
Western Ontario and McMaster Universities Index
Scores are on a scale of 0 through 96, with a higher score indicating a worse function level.
Measured: From enrollment to 3 months
Pain Visual Analog Scale
scale of 0 through 10, with 10 being the highest pain level.
Measured: From enrollment to 3 months
Secondary outcomes (1)
Immediate change in pVAS (Pain Visual Analog Scale)
pVAS scores from baseline and immediately after injection will be compared. pVAS is on a scale of 0 through 10, with 10 being the highest pain level.
Measured: From enrollment to immediately after intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2026
- Study start12 Dec 2025
- Primary completion8 Dec 2026 (estimated)
- Study completion8 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Knee Arthritis OsteoarthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 140 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sosi Dzhugarian
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Sosi Dzhugarian, Community Memorial Health System
- Investigators
- Griffin Elbert, DO, Principal investigator, Community Memorial Healthcare
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07544576
- Sponsor's protocol ID
- 1402691
- Acronym
- PRECISION-Knee
- Status last verified
- Apr 2026
- First submitted
- 9 Apr 2026
- Last updated
- 22 Apr 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non-Inferiority Study Comparing Treatment of Primary Knee Osteoarthritis With Intra-Articular Triamcinolone Injections Using 40mg With Landmark Guidance and 20mg With Ultrasound Guidance: The PRECISION-Knee Trial (PRospective Evaluation of the Clinical Impact of Steroid Injection Options iN Knee Osteoarthritis)
- ClinicalTrials.gov ID
- NCT07544576
- Acronym / sponsor ID
- PRECISION-Knee / 1402691
- Conditions
- Knee Arthritis Osteoarthritis
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 140 participants (estimated)
- Lead sponsor
- Sosi DzhugarianUniversity, hospital or other
- Study start
- 12 Dec 2025 (actual)
- Primary completion
- 8 Dec 2026 (estimated)
- Study completion
- 8 Dec 2026 (estimated)
- First posted
- 22 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether a lower dose of corticosteroid injection with ultrasound-guidance for the treatment of knee osteoarthritis can be as effective as a higher dose that is landmark-guided. With landmark-guided dosing, it may be reasonable to use a higher amount of corticosteroid in order to ensure a sufficient amount of the medication is administered, however these injections carry the risk of side effects. Alternatively, with the use of ultrasound, it may be reasonable to use less corticosteroid, possibly decreasing the risk of side effects and increasing patient satisfaction.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 40mg landmark-guided triamcinolone knee joint injection | Active comparator | Drug: Triamcinolone knee injection without ultrasound guidance |
| 20mg ultrasound-guided triamcinolone knee injection | Experimental | Combination Product: Triamcinolone knee injection with ultrasound guidance |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Subjects who have already been evaluated within at least one of the 4 study clinics with any of the 3 providers who will be administering the treatment
- Males or females age 50 and older
- Already had completion of imaging of the affected knee(s) via radiography and/or MRI
- Imaging demonstrates osteoarthritis of any severity
- Diagnosis of primary osteoarthritis of one or both knees
Key exclusion criteria (10 listed)
- Skin infection at or near area of injection site
- Recent fracture of the same knee joint within past 6 months
- Uncontrolled bleeding disorder
- Intra-articular corticosteroid injection within past 3 months
- Intra-articular HA injection within the past 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Triamcinolone knee injection without ultrasound guidance3mL lidocaine (without epinephrine) 1% solution combined with 1mL triamcinolone acetonide injectable solution, USP (40mg per mL) | Drug | 40mg landmark-guided triamcinolone knee joint injection |
| Triamcinolone knee injection with ultrasound guidance3mL lidocaine (without epinephrine) 1% solution combined with 0.5mL triamcinolone acetonide injectable solution, USP (40mg per mL) | Combination product | 20mg ultrasound-guided triamcinolone knee injection |
Primary outcome
Western Ontario and McMaster Universities Index
Time frame: From enrollment to 3 months
Scores are on a scale of 0 through 96, with a higher score indicating a worse function level.
Pain Visual Analog Scale
Time frame: From enrollment to 3 months
scale of 0 through 10, with 10 being the highest pain level.
1 secondary outcome
Immediate change in pVAS (Pain Visual Analog Scale)
Time frame: From enrollment to immediately after intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2026.
Related trials for Knee Arthritis Osteoarthritis
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
RecruitingObservational study
Exploring Factors Linked to Worsening Over Time in People With Early-stage Knee Osteoarthritis and Those With Prior Proven Acute Knee Injury.
Knee Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Griffin Elbert, DO principal investigator
Community Memorial Healthcare
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Triamcinolone knee injection without ultrasound guidance and Triamcinolone knee injection with ultrasound guidance in people with Knee Arthritis Osteoarthritis, run by Sosi Dzhugarian at 4 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 22 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Western Ontario and McMaster Universities Index (time frame: From enrollment to 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2026.